Press Release Stockholm, Sweden, November 2, 2023 Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data Three abstracts.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program.
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration .